Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has allowed Acorda Therapeutics' US Patent Application No. 11/010,828 entitled 'Sustained Release Aminopyridine Composition.'
Subscribe to our email newsletter
The patent application covers methods to improve walking in patients with multiple sclerosis (MS) by administering 10mg of sustained release 4-aminopyridine (dalfampridine) twice daily.
Acorda is marketing Ampyra (dalfampridine) extended release tablets, 10 mg as a treatment to improve walking in people with MS.